FDA panel recommends BPC-157, KPV, TB-500, MOTS-c

United States: On July 23 and 24, 2026, the Pharmacy Compounding Advisory Committee (PCAC) of the US Food and Drug Administration (FDA) recommended by narrow margins that the peptides BPC-157, KPV, TB-500, and MOTS-c be added to the 503A bulk drug substances list for compounding pharmacies. Emideltide (DSIP) was the only one of the seven reviewed peptides to be rejected. For peptide users, the vote is an important step: the recommendation is not an FDA approval, but it changes the regulatory landscape in the US and the debate over the safety and sourcing of these substances.

Key outcomes of the PCAC vote on peptides

• On July 24, 2026, the FDA advisory committee PCAC recommended by a vote of 8 to 6 (with one abstention) that BPC-157, KPV, and TB-500 be added to the 503A bulk drug substances list for compounding pharmacies [2][6].
• MOTS-c was also assessed positively by a vote of 7 to 5 (with two abstentions), despite objections from FDA scientists regarding the lack of human injection data [6].
• Emideltide (DSIP) was rejected by a vote of 7 to 6 (with one abstention), making it the only rejection during the two-day review [9].
• The recommendation is not an immediate approval: compounding pharmacies may only manufacture the peptides after a multi-stage rulemaking process is completed, which typically takes 8-12 months [6].

What the PCAC recommendation means for peptide users

For users of BPC-157, KPV, TB-500, or MOTS-c, the PCAC recommendation from July 2026 is a double-edged signal: it opens up prospects for future legal compounding, but it does not confirm the clinical efficacy or safety of these substances. According to PharmExec (2026), the vote does not constitute an FDA approval and does not demonstrate clinical benefit [6]. Despite the lack of human data, the committee saw potential benefit, but it continues to emphasize the experimental status of the active ingredients.

FDA scientists had previously recommended rejecting all seven peptides due to the lack of robust data on safety risks, clinical efficacy, and standardized manufacturing processes [9]. By overriding this agency position with a narrow majority, the advisory committee highlighted the controversy surrounding the current evidence base. While the substances are now regulatorily closer to legal pharmacy compounding, they remain scientifically in the experimental stage.

Why was Emideltide (DSIP) rejected?

Emideltide, also known as Delta-Sleep-Inducing-Peptide (DSIP), is a neuropeptide consisting of nine amino acids intended for the treatment of sleep disorders. The PCAC committee voted 7 to 6 against adding it to the 503A bulk drug substances list [3][9]. The committee cited the low quality of evidence, insufficient characterization of the bulk drug substance, and the availability of already approved therapeutic alternatives as the primary reasons for this sole rejection during the two-day review [9].

Specific safety concerns raised by the FDA reinforced the negative vote. According to agency documents (2026), Emideltide carries a relevant immunogenicity risk via certain routes of administration, as well as analytical challenges related to peptide impurities and API characterization [8]. Additionally, the FDA pointed to an unresolved potential for dependence through opioid-dependent mechanisms, which remained uncharacterized in nonclinical studies [7]. The few available human studies are outdated, have small cohorts, and do not provide robust evidence under controlled study designs [3].

What does the 503A bulk drug substances list mean for compounding pharmacies?

The 503A bulk drug substances list is a US registry of permissible active ingredients that licensed compounding pharmacies in the US may process under defined conditions for individual patient prescriptions [5]. Inclusion on this list creates the legal basis for manufacturing that is defensible under US federal law, whereas mere removal from the interim category 2 list does not yet constitute authorization to manufacture [5].

The regulatory implementation process following the PCAC vote is multi-stage: after removal from category 2 and the PCAC recommendation, classification into category 1 follows through a formal notice-and-comment rulemaking process [6]. This administrative procedure typically takes 8-12 months to achieve final legal certainty [6]. Compounding pharmacies are still prohibited from preparing the recommended peptides before this process is completed.

What impact will the vote have on the peptide gray market?

Future legal availability through compounding pharmacies could reduce demand on the unregulated gray market, but it does not immediately solve the existing quality problems with peptides. As a central hurdle, FDA scientists highlighted the lack of binding chemical definitions and specifications, which leaves the identity, purity, and comparability of many batches uncertain [6].

Until regulated supply chains are established, independent quality testing of peptides remains essential. Users should look for independent laboratory analyses and use information resources such as the Protection when ordering / Vendor Radar section to avoid contamination or underdosing. Specific classifications regarding legal status and approval situation are available on the BPC-157 page in the Peptide Library.

What happens next in the FDA regulatory process for peptides?

The PCAC vote marks an important preliminary decision but does not complete the FDA's regulatory process. Only after the notice-and-comment process, which is expected to take 8-12 months, will the FDA make a final decision on the binding category 1 classification [6]. Until that decision, the regulatory status for pharmacies remains unchanged, and the substances continue to be considered experimental due to the lack of complete safety and efficacy evidence.

The next steps of the US authorities will be continuously analyzed and documented. Comprehensive scientific profiles on mechanisms of action and study data are available in the Peptide Library. This article is for informational purposes only and does not replace medical advice; for medical questions, qualified professionals should be consulted.